Economia
Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Smith+Nephew continues to pioneer in Sports Medicine and is excited to introduce a new category called Spatial Surgery - a revolutionary new frontier in arthroscopic surgical innovation. This 510(k)-pending technology called the TESSA Spatial Surgery System (Tracking Enabled Spatial Surgery Assistant) plans to combine personalized operative planning with a real-time, tracking enabled device using advanced imaging and augmented reality guidance to assist a surgeon in decision making. Learn more at www.spatialsurgery.com
Smith+Nephew's CARTIHEAL AGILI-C Cartilage Repair Implant is an FDA approved device that was previously granted breakthrough designation and is now evolving the cartilage repair landscape. The unique properties of the implant enable physicians to surgically treat patients that previously had no access to cartilage repair procedures. In a large randomized controlled trial, when compared to the surgical standard of care, the CARTIHEAL AGILI-C implant demonstrated:
The use of the CARTIHEAL AGILI-C Implant in the presence of osteoarthritis will be featured during OrthoDome at AAOS on Wednesday, March 12, from 11:16-11:31 am PST. You can learn more by visiting the CARTIHEAL AGILI-C webpage here.
The REGENETEN Bioinductive Implant is a scaffold made from highly purified type I collagen fibers and has changed the way surgeons treat tendon injuries for more than ten years. Clinical studies in rotator cuff repair have demonstrated results that surpass the current standard of care:
In addition to continued value in rotator cuff repair, usage of the REGENETEN Implant continues to increase in tendons around the body, including those in the hip, knee, and foot & ankle, where surgeons recognize its potential to improve tendon healing. You can learn more by visiting the REGENETEN webpage here.
To learn more about Smith+Nephew's Sports Medicine joint repair solutions and enabling technologies, please visit our booth (#3729) at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego March 11-13, 2025, or visit www.smith-nephew.com.
- ends –
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
* Debridement or microfracture
** Over a 2- and 4-year follow-up
*** Re-tear: 8.3% vs 25.8%; Relative risk=0.32 [95% Confidence Interval 0.13-
0.83]; p=0.0106.
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti